Role of Corticotropin Releasing Factor receptor subtype 1 in stress-related functional colonic alterations: Implications in irritable bowel syndrome

European Journal of Surgery, Supplement

Volumn 168, Issue 587, 2002, Pages 16-22

  Taché, Yvette ^a   Martinez, Vicente ^a   Million, Mulugeta ^a   Maillot, Celine ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anxiety; Colonic motility; CRF; CRF antagonist; CRF receptor; IBS; Stress; Visceral pain

Indexed keywords

5 CHLORO 4 [N (CYCLOPROPYLMETHYL) N PROPYLAMINO] 2 METHYL 6 (2,4,6 TRICHLOROANILINO)PYRIMIDINE; ANTALARMIN; ASTRESSIN; BUTYL[2,5 DIMETHYL 7 (2,4,6 TRIMETHYLPHENYL) 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL]ETHYLAMINE; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR; INTERLEUKIN 1BETA; PROSTAGLANDIN E2; RECEPTOR SUBTYPE;

ABDOMINAL PAIN; CONFERENCE PAPER; CORTICOTROPIN RELEASE; DEGRANULATION; DEPRESSION; FUNCTIONAL DISEASE; HUMAN; HYPERALGESIA; HYPERPLASIA; ION PERMEABILITY; IRRITABLE COLON; MAST CELL; MOLECULAR CLONING; MOTOR PERFORMANCE; MUCUS SECRETION; NONHUMAN; PAIN THRESHOLD; PHYSIOLOGY; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; PROTEIN ANALYSIS; REDUCTION; SIGNAL TRANSDUCTION; STIMULATION; STRESS; ANXIETY; BRAIN; COLON; DRUG ANTAGONISM; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT; REVIEW;

ANXIETY; BRAIN; COLON; DEPRESSION; HUMANS; HYPERALGESIA; IRRITABLE BOWEL SYNDROME; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE;

EID: 0036961118     PISSN: 1102416X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (70)

1. Arborelius L, Owens MJ, Plotsky PM, Nemeroff CB. The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol 1999; 160: 1-12.
2. Bakshi VP, Kalin NH. Corticotropin-releasing hormone and animal models of anxiety: gene-environment interactions. Biol Psychiatry 2000; 48: 1175-1198.
3. Bennett EJ, Tennant CC, Piesse C, Badcock J, Kellow J. Level of chronic life stress predicts clinical outcome in irritable bowel syndrome. Gut 1998; 43: 256-261.
4. Bonaz B, Taché Y. Water-avoidance stress-induced c-fos expression in the rat brain and stimulation of fecal output: role of corticotropin-releasing factor. Brain Res 1994; 641: 21-28.
5. Brady LS, Gold PW, Herkenham M, Lynn AB, Whitfield HJ, Jr. The antidepressants fluoxetine, idazoxan and phenelzine alter corticotropin-releasing hormone and tyrosine hydroxylase mRNA levels in rat brain: therapeutic implications. Brain Res 1992; 572: 117-125.
6. Camilleri M. Management of the irritable bowel syndrome. Gastroenterology 2001; 120: 652-668.
7. Castagliuolo I, Lamont JT, Qiu B, et al. Acute stress causes mucin release from rat colon: role of corticotropin releasing factor and mast cells. Am J Physiol 1996; 271: G884-G892.
8. Chen C, Dagnino JrR, De Souza EB, et al. Design and synthesis of a series of non-peptide high affinity human corticotropin-releasing factor receptor antagonists. J Med Chem 1996; 39: 4358-4360.
9. Cochrane SW, Gibson MS, Myers DA, et al. Role of corticotropin-releasing factor-1 (CRF1)-receptor mediated mechanisms in neural pathways modulating colonic hypersensitivity. Gastroenterology 120 suppl 1, A-7. 2001.
10. Creed F. The relationship between psychosocial parameters and outcome in irritable bowel syndrome. Am J Med 1999; 107: 74S-80S.
11. De Bellis MD, Gold PW, Geracioti TD Jr, Listwak SJ, Kling MA. Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression. Am J Psychiatry 1993; 150: 656-657.
12. Donaldson CJ, Sutton SW, Perrin MH, et al. Cloning and characterization of human urocortin. Endocrinology 1996; 137: 2167-2170.
13. Enck P, Holtmann G. Stress and gastrointestinal motility in animals: a review of the literature. J Gastrointest Motil 1992; 1: 83-90.
14. Fargeas M-J, Fioramonti J, Buéno L. Central action of interleukin-1β on intestinal motility in rats: mediation by two mechanisms. Gastroenterology 1993; 104: 377-383.
15. Ford MJ, Camilleri M, Zinsmeister AR, Hanson RB. Psychosensory modulation of colonic sensation in the human transverse and sigmoid colon. Gastroenterology 1995; 109: 1772-1780.
16. Fukudo S, Nomura T, Hongo M. Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome. Gut 1998; 42: 845-849.
17. Gilligan PJ, Robertson DW, Zaczek R. Corticotropin releasing factor (CRF) receptor modulators: progress and opportunities for new therapeutic agents. J Med Chem 2000; 43: 1641-1660.
18. Gué M, Del Rio-Lacheze C, Eutamene H, Theodorou V, Fioramonti J, Bueno L. Stress-induced visceral hypersensitivity to rectal distension in rats: role of CRF and mast cells. Neurogastroenterol Motil 1997; 9: 271-279.
19. Gué M, Junien JL, Buéno L. Conditioned emotional response in rats enhances colonic motility through the central release of corticotropin-releasing factor. Gastroenterology 1991; 100: 964-970.
20. Gulyas J, Rivier C, Perrin M, et al. Potent, structurally constrained agonists and competitive antagonists of corticotropin-releasing factor. Proc Natl Acad Sci USA 1995; 92: 10575-10579.
21. Gunter WD, Shepard JD, Foreman RD, Myers DA, Greenwood-Van Meerveld B. Evidence for visceral hypersensitivity in high-anxiety rats. Physiol Behav 2000; 69: 379-382.
22. Guthrie E, Creed F, Dawson D, Tomenson B. A controlled trial of psychological treatment for the irritable bowel syndrome. Gastroenterology 1991; 100: 450-457.
23. Habib KE, Weld KP, Rice KC, et al. Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates. Proc Natl Acad Sci USA 2000; 97: 6079-6084.
24. Heinrichs SC, Taché Y. Therapeutic potential of CRF receptor antagonists: a gut-brain perspective. Expert Opin Investig Drugs 2001; 10: 647-659.
25. Hikichi T, Akiyoshi J, Yamamoto Y, Tsutsumi T, Isogawa K, Nagayama H. Suppression of conditioned fear by administration of CRF receptor antagonist CP-154,526. Pharmacopsychiatry 2000; 33: 189-193.
26. Holsboer F. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. J Psychiatr Res 1999; 33: 181-214.
27. Holsboer F. Stress, hypercortisolism and corticosteroid receptors in depression: implications for therapy. J Affect Disord 2001; 62: 77-91.
28. Hua X-Y, Yaksh TL. Pharmacology of the effects of bradykinin, serotonin, and histamine on the release of calcitonin gene-related peptide from C-fiber terminals in the rat trachea. J Neurosci 1993; 13: 1947-1953.
29. Kamm MA. The role of psychosocial factors in functional gut disease. Eur J Surg 1998; 583: 37-40.
30. Keck ME, Holsboer F. Hyperactivity of CRH neuronal circuits as a target for therapeutic interventions in affective disorders. Peptides 2001; 22: 835-844.
31. Koob GF, Heinrichs SC. A role for corticotropin releasing factor and urocortin in behavioral responses to stressors. Brain Res 1999; 848: 141-152.
32. Lembo T, Plourde V, Shui Z, Fullerton S, Mertz H, Taché Y, Sytnik B, Munakata J, Mayer E. Effects of the corticotropin-releasing factor (CRF) on rectal afferent nerves in humans. Neurogastroenterol Motil 1996; 8: 9-18.
33. Lenz HJ, Burlage M, Raedler A, Greten H. Central nervous system effects of corticotropin-releasing factor on gastrointestinal transit in the rat. Gastroenterology 1988; 94: 598-602.
34. Lenz HJ, Raedler A, Greten H, Vale WW, Rivier JE. Stress-induced gastrointestinal secretory and motor responses in rats are mediated by endogenous corticotropin-releasing factor. Gastroenterology 1988; 95: 1510-1517.
35. Lewis K, Li C, Perrin MH, Blount A, et al. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc Natl Acad Sci USA 2001; 98: 7570-7575.
36. Lu L, Liu D, Ceng X, Ma L. Differential roles of corticotropin-releasing factor receptor subtypes 1 and 2 in opiate withdrawal and in relapse to opiate dependence. Eur J Neurosci 2000; 12: 4398-4404.
37. Lydiard RB, Falsetti SA. Experience with anxiety and depression treatment studies: implications for designing irritable bowel syndrome clinical trials. Am J Med 1999; 107: 65S-73S.
38. Maillot C, Million M, Wei JY, Gauthier A, Taché Y. Peripheral corticotropin-releasing factor and stress-stimulated colonic motor activity involve type 1 receptor in rats. Gastroenterology 2000; 119: 1569-1579.
39. Malaguarnera M, Laurino A, Di FI, et al. Neuropsychiatric effects and type of INF-alpha in chronic hepatitis C. J Interferon Cytokine Res 2001; 21: 273-278.
40. Mancinelli R, Azzena GB, Diana M, Forgione A, Fratta W. In vitro excitatory actions of corticotropin-releasing factor on rat colonic motility. J Auton Pharmacol 1998; 18: 319-324.
41. Martinez V, Rivier J, Wang L, Taché Y. Central injection of a new corticotropin-releasing factor (CRF) antagonist, astressin, blocks CRF- and stress-related alterations of gastric and colonic motor function. J Pharmacol Exp Ther 1997; 280: 754-760.
42. Martinez V, Taché Y. Role of CRF receptor 1 in central CRF-induced stimulation of colonic propulsion in rats. Brain Res 2001; 893: 29-35.
43. Mayer EA, Naliboff BD, Chang L, Coutinho SV. V. Stress and irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2001; 280: G519-G524.
44. McCarthy JR, Heinrichs SC, Grigoriadis DE. Recent advances with the CRF1 receptor: design of small molecule inhibitors, receptor subtypes and clinical indications. Curr Pharm Des 1999; 5: 289-315.
45. 1 receptor in conscious rats. Am J Physiol Gastrointest Liver Physiol 2002; 282; G857-G865.
46. 2-mediated action on gastric transit in rats. Am J Physiol Gastrointest Liver Physiol 2002; 282: G34-40.
47. Million M, Wang L, Martinez V, Taché Y. Differential Fos expression in the paraventricular nucleus of the hypothalamus, sacral parasympathetic nucleus and colonic motor response to water avoidance stress in Fischer and Lewis rats. Brain Res 2000; 877: 345-353.
48. Mönnikes H, Schmidt BG, Raybould HE, Taché Y. CRF in the paraventricular nucleus mediates gastric and colonic motor response to restraint stress. Am J Physiol 1992; 262: G137-G143.
49. Mönnikes H, Schmidt BG, Taché Y. Psychological stress-induced accelerated colonic transit in rats involves hypothalamic corticotropin-releasing factor. Gastroenterology 1993; 104: 716-723.
50. Mönnikes H, Schmidt BG, Tebbe J, Bauer C, Taché Y. Microinfusion of corticotropin releasing factor into the locus coeruleus/subcoeruleus stimulates colonic motor function in rats. Brain Res 1994; 644: 101-108.
51. North CS, Alpers DH, Thompson SJ, Spitznagel EL. Gastrointestinal symptoms and psychiatric disorders in the general population: findings from NIMH epidemiologic catchement area project. Dig Dis Sci 1996; 41: 633-640.
52. Perrin MH, Vale WW. Corticotropin releasing factor receptors and their ligand family. Ann N Y Acad Sci 1999; 885: 312-328.
53. Raber J, Koob GF, Bloom FE. Interferon-alpha and transforming growth factor-beta 1 regulate corticotropin-releasing factor release from the amygdala: comparison with the hypothalamic response. Neurochem Int 1997; 30: 455-463.
54. Rao SS, Hatfield RA, Suls JM, Chamberlain MJ. Psychological and physical stress induce differential effects on human colonic motility. Am J Gastroenterol 1998; 93: 985-990.
55. Reyes TM, Lewis K, Perrin MH, et al. Urocortin II: A member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc Natl Acad Sci USA 2001; 98: 2843-2848.
56. Santos J, Saunders PR, Hanssen NPM, et al. Corticotropin-releasing hormone mimics stress-induced rat colonic epithelial pathophysiology in the rat. Am J Physiol 1999; 277: G391-G399.
57. Schulz DW, Mansbach RS, Sprouse J, et al. CP-154, 526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors. Proc Natl Acad Sci USA 1996; 93: 10477-10482.
58. Steckler T, Holsboer F. Corticotropin-releasing hormone receptor subtypes and emotion. Biol Psychiatry 1999; 46: 1480-1508.
59. Sternberg EM, Young III WS, Bernardini R, et al. A central nervous system defect in biosynthesis of corticotropin-releasing hormone is associated with susceptibility to streptococcal cell wall-induced arthritis in Lewis rats. Proc Natl Acad Sci USA 1989; 86: 4771-4475.
60. Taché Y, Martinez V, Million M, Wang L. Stress and the gastrointestinal tract III. Stress-related alterations of gut motor function: role of brain corticotropin-releasing factor receptors. Am J Physiol 2001; 280: G173-G177.
61. Talley NJ. Irritable bowel syndrome: disease definition and symptom description. Eur J Surg 1998; 583: 24-28.
62. Tong MJ, Reddy KR, Lee WM, et al. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group. Hepatology 1997; 26: 747-754.
63. Turnbull AV, Rivier C. Corticotropin-releasing factor (CRF) and endocrine response to stress: CRF receptors, binding protein, and related peptides. Proc Soc Exp Biol Med 1997; 215: 1-10.
64. Turnbull AV, Rivier CL. Regulation of the hypothalamic-pituitary-adrenal axis by cytokines: actions and mechanisms of action. Physiol Rev 1999; 79: 1-71.
65. Vale W, Spiess J, Rivier C, Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and β-endorphin. Science 1981; 213: 1394-1397.
66. Vaughan J, Donaldson C, Bittencourt J, et al. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 1996; 378: 287-292.
67. Whitehead WE, Crowell MD, Robinson JC, Heller BR, Schuster MM. Effect of stressful life events on bowel symptoms: subjects with irritable bowel syndrome compared with subjects without bowel dysfunction. Gut 1992; 33: 825-830.
68. Williams CL, Peterson JM, Villar RG, Burks TF. Corticotropin-releasing factor directly mediates colonic responses to stress. Am J Physiol 1987; 253: G582-G586.
69. 1 receptors mediate consensus interferon-α YM643-induced depression-like behavior in mice. J Pharmacol Exp Ther 2000; 292: 181-187.
70. Zobel AW, Nickel T, Kunzel HE, et al. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res 2000; 34: 171-181.